Monopar TherapeuticsMNPR
MNPR
About: Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Employees: 16
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,700% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 1
94% more funds holding
Funds holding: 18 [Q4 2024] → 35 (+17) [Q1 2025]
91% more capital invested
Capital invested by funds: $57.1M [Q4 2024] → $109M (+$52.2M) [Q1 2025]
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
4.91% more ownership
Funds ownership: 42.41% [Q4 2024] → 47.31% (+4.91%) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$60
41%
upside
Avg. target
$67
57%
upside
High target
$74
73%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Cantor Fitzgerald Kristen Kluska | 73%upside $74 | Overweight Initiated | 7 Jul 2025 |
Chardan Capital Keay Nakae | 41%upside $60 | Buy Initiated | 23 Jun 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know
The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to a 51.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
GlobeNewsWire
1 month ago
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “us” and “our”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, in collaboration with Excel Diagnostics and Nuclear Oncology Center (“EDNOC”), a premier diagnostic medical imaging and therapeutic nuclear medicine center, today announced that the physician-sponsored Expanded Access Program (“EAP”) for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu has received authorization to proceed from the U.S. Food and Drug Administration (“FDA”).
Neutral
GlobeNewsWire
1 month ago
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
WILMETTE, Ill., June 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that it will be added to the broad-market Russell 3000® Index, with automatic inclusion in the small-cap Russell 2000® Index, after the close of U.S. equity markets on June 27, 2025.
Neutral
GlobeNewsWire
2 months ago
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced first quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On May 7, 2025, Monopar presented long-term efficacy and safety data for ALXN1840 (tiomolybdate choline) at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025, a leading global conference in liver disease.
Neutral
GlobeNewsWire
2 months ago
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025, one of the most prominent global conferences in liver disease. Monopar's late-breaker poster presentation is available at the following link: https://www.monopartx.com/pipeline/ALXN1840/EASL-poster-may-2025.
Neutral
GlobeNewsWire
3 months ago
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025
WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease has been accepted for a late-breaker poster presentation at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025. EASL is recognized as one of the premier events in the hepatology space and will be held in Amsterdam, Netherlands from May 7 – 10, 2025.
Neutral
GlobeNewsWire
4 months ago
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
WILMETTE, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced fourth quarter and full-year 2024 financial results and summarized recent developments.
Positive
Zacks Investment Research
4 months ago
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going
Monopar Therapeutics (MNPR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Neutral
PRNewsWire
6 months ago
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics
Monopar's pipeline includes clinical-stage radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease NORTH CHICAGO, Ill. , Jan. 23, 2025 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science announced that Monopar Therapeutics is the latest biotech company to join the Helix 51 biomedical incubator community.
Positive
Zacks Investment Research
6 months ago
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
Monopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate.
Charts implemented using Lightweight Charts™